Immunocore (IMCR) announced that Kimmtrak five-year overall survival, OS, was presented in an oral session at the American Association for Cancer Research, AACR, 2026 meeting. This is the longest, prospective Phase 3 randomized trial in patients with unresectable or metastatic uveal melanoma – a disease with a very poor prognosis and a historical survival rate of less than 5% at 5 years. Kimmtrak doubled the likelihood of being alive at five years, with an OS for Kimmtrak of 16% versus 8% in the control arm. These results also represent the longest follow-up reported for any T cell engager in a solid tumor.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore: KIMMTRAK’s Durable Leadership in Metastatic Uveal Melanoma Underpins Buy Rating and $100 Target
- Immunocore (IMCR): Clinical Momentum, Credible Management, and Industry Visibility Support Buy Rating
- Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
- Immunocore downgraded to Hold from Buy at Jefferies
- Immunocore: Strong KIMMTRAK Execution, Robust Late-Stage Pipeline, and Cash-Funded Catalysts Support Buy Rating and $100 Target